Development of predictive pharmacokinetic simulation models for drug discovery.
暂无分享,去创建一个
P J Sinko | G. Grass | D. Norris | P. Sinko | D A Norris | G D Leesman | G M Grass | G. Leesman | Daniel A. Norris | Glen D. Leesman | George M. Grass
[1] Susan Budavari,et al. The Merck index , 1998 .
[2] W R Gillespie,et al. Convolution-based approaches for in vivo-in vitro correlation modeling. , 1997, Advances in experimental medicine and biology.
[3] J. C. Martin,et al. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine , 1983, Antimicrobial Agents and Chemotherapy.
[4] S. Walker,et al. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). , 1988, British journal of clinical pharmacology.
[5] G L Amidon,et al. Novel approach to the analysis of in vitro-in vivo relationships. , 1996, Journal of pharmaceutical sciences.
[6] P. Artursson,et al. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.
[7] J. Mcainsh,et al. Pharmacokinetic studies with atenolol in the dog , 1983, Biopharmaceutics & drug disposition.
[8] D. Jung,et al. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients. , 1995, Clinical therapeutics.
[9] G L Amidon,et al. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[10] J. Polli,et al. Prediction of dissolution-absorption relationships from a dissolution/Caco-2 system. , 1999, International journal of pharmaceutics.
[11] S. Itai,et al. In vitro dissolution tests corresponding to the in vivo dissolution of clarithromycin tablets in the stomach and intestine. , 1995, Chemical & pharmaceutical bulletin.
[12] H. Frey,et al. Pharmacokinetics of naproxen in the dog. , 1981, American journal of veterinary research.
[13] Sietsema Wk,et al. The absolute oral bioavailability of selected drugs , 1989 .
[14] J. C. Martin,et al. 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine: a new potent and selective antiherpes agent. , 1983, Journal of medicinal chemistry.
[15] G. Grass,et al. Simulation models to predict oral drug absorption from in vitro data , 1997 .
[16] J Devane,et al. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption. , 1999, Statistics in medicine.
[17] D. Jung,et al. Effect of Food on the Relative Bioavailability of Oral Ganciclovir , 1996, Journal of clinical pharmacology.
[18] S. Spector,et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. , 1995, The Journal of infectious diseases.
[19] T. Kennedy. Managing the drug discovery/development interface , 1997 .
[20] G. Amidon,et al. Absorption potential: estimating the fraction absorbed for orally administered compounds. , 1985, Journal of pharmaceutical sciences.
[21] J. Dressman,et al. Mixing-tank model for predicting dissolution rate control or oral absorption. , 1986, Journal of pharmaceutical sciences.
[22] PHARMACOKINETIC STUDIES , 1976 .